Connect with us

Health

WHO recommends a clinical trial of Ebola vaccine against Bundibugyo virus

info

Published

on

World Health Organisation.jpg

MTN ADVERT

The World Health Organisation (WHO) has recommended that a vaccine called Ervebo be prioritised for a randomised clinical trial against Bundibugyo virus disease in the Democratic Republic of Congo (DRC).
The recommendation followed preliminary animal study data suggesting that the vaccine may provide some cross-protection against the disease, particularly in reducing deaths.

WHO’s Technical Advisory Group on Candidate Vaccine Prioritisation made the recommendation at its third meeting on 31 July, after reviewing available evidence on the vaccine’s safety, efficacy, availability and feasibility.

The development comes as the DRC continues to respond to an outbreak of Ebola disease caused by the Bundibugyo virus, which was declared on 15 May 2026.

As of 30 July, WHO had recorded 3,605 confirmed cases and 1,587 deaths from the outbreak in the DRC.

Why Ervebo is being considered

The advisory group’s recommendation is significant because Ervebo was developed specifically against Ebola virus disease caused by the Ebola Zaire virus, rather than the Bundibugyo virus.

PT WHATSAPP CHANNEL

According to WHO, the group initially advised against using Ervebo outside carefully designed research settings because its effectiveness against Bundibugyo virus disease remained uncertain.

However, preliminary animal study data indicate that Ervebo may confer some cross-protection against Bundibugyo virus disease, particularly by reducing mortality.

The latest evidence prompted the advisory group to recommend that Ervebo be prioritised for a randomised clinical trial to determine its effectiveness against the disease.

What is the Bundibugyo virus?

The Bundibugyo virus causes Ebola disease. It is distinct from the Ebola virus that Ervebo was specifically developed to protect against.

The Bundibugyo virus disease outbreak in the DRC is the first of its kind in the country. WHO says there is currently no licensed vaccine or specific treatment for Bundibugyo virus disease.

The disease is a severe infection, and previous Bundibugyo virus disease outbreaks have recorded case fatality rates ranging from 30 to 50 per cent, according to WHO.

Safety concerns

According to WHO, the advisory group found no identified safety concerns with the use of Ervebo among contacts of confirmed cases during a Bundibugyo virus disease outbreak.

READ ALSO: WHO raises alarm as DR Congo’s Ebola outbreak surpasses 3,600 cases

However, the experts stressed that the vaccine’s effectiveness against Bundibugyo virus disease and its ability to prevent transmission have not been established.

They therefore recommended that these questions be evaluated through clinical research.

WHO said a vaccine specifically developed against the Bundibugyo virus would remain the preferred option, although preliminary data on such candidates are currently unavailable.

The advisory group also emphasised the need to facilitate large-scale vaccine production and access if future evidence demonstrates sufficient efficacy to protect affected populations.


Discover more from Premium Times Nigeria

Subscribe to get the latest posts sent to your email.

Continue Reading
Click to comment

Leave a Reply

Your email address will not be published. Required fields are marked *

Health

FG urges early cancer detection, says delayed diagnosis complicates treatment

info

Published

on

By

Admin ajax 6.jpg

MTN ADVERT

The federal government has underscored the importance of early cancer detection, saying the stage at which the disease is diagnosed determines the treatment approach and chances of cure.

Uchechukwu Nwokwu, National Coordinator, National Cancer Control Plan (NCCP), Federal Ministry of Health and Social Welfare, said this in an interview with the News Agency of Nigeria (NAN) on Sunday in Abuja.

Mr Nwokwu also explained how cancer progresses through four stages, adding that it is not a single disease but a group of diseases that could affect different organs and behave differently depending on the type of cancer and the cells from which it originated.

According to him, cancer begins when abnormal cells develop within a particular organ or body system, with the extent of spread determining its stage.

He said Stage One cancer referred to a disease that remained within the area where it originated and had not spread beyond that location.

PT WHATSAPP CHANNEL

“When the cancer may arise from a small cell inside the organ of a particular system of the body, and as long as it is within the area it originated, it is an early stage, stage one,” he said.

Mr Nwokwu said Stage Two occurs when the cancer has moved beyond its original area but remains confined within the affected organ.

He explained that Stage Three is when the disease has grown beyond the affected organ but remains within the same body system or surrounding region.

“For example, if a breast cancer is growing beyond the breast and affects the chest wall, which is hosting the breast, that’s Stage Three,” he said.

The coordinator said Stage Four is the most advanced stage, occurring when the cancer has spread from the original organ to other systems or distant parts of the body.

He said such a spread is known as metastasis.

“So when it leaves the whole of where it’s growing, it’s a different system, we call it metastasis. That’s stage four,” he said.

Mr Nwokwu explained that breast cancer, for instance, could spread to the brain, bones, liver or lungs, with tests showing that a tumour in those locations originated from the breast.

He said Stage Four cancer is particularly difficult to manage because treatment is no longer focused solely on the original organ.

“So that means you can see breast cancer affecting some in the brain. You can see a tumour in the brain that’s actually from the breast,” he said.

Mr Nwokwu said the stage at which cancer is detected has significant implications for treatment and the possibility of achieving a cure.

He explained that some stage one cancers could potentially be cured through surgery alone because the disease remained confined to its site of origin.

“If you have somebody who has a breast cancer in stage one, like I said, it’s still within where it started from,” he said.

“You might just cut off that place and do a surgery that can just take a small part of the normal tissue where it has not affected, and with that surgery alone, the person is completely cured of that cancer.”

According to him, surgery can also be effective for some stage two cancers because the disease remains confined to the organ.

He said stage two and stage three cancers could, however, require combinations of treatment, including surgery, chemotherapy and radiotherapy.

Mr Nwokwu explained that doctors could also use what is known as neoadjuvant or adjuvant therapy alongside surgery, depending on the patient’s condition.

He said targeted therapy is another treatment option for cancers driven by particular hormones or biological mechanisms.

The coordinator cited prostate cancer as an example, explaining that some patients could undergo removal of the testes to reduce testosterone, a hormone that could stimulate the growth of prostate cancer.

He, however, noted that some advanced prostate cancers could become resistant to this approach, a condition known as castration-resistant prostate cancer, requiring other medicines to control disease progression.

Mr Nwokwu said treatment of stage four cancer is more complex because the disease could involve several parts of the body.

He explained that chemotherapy could be useful in some circumstances because it is a systemic treatment that can reach cancer cells throughout the body.

He, however, said that radiotherapy had to be applied more selectively depending on where the cancer had spread and the patient’s overall condition.

READ ALSO: Health minister seeks increased investment in radiopharmaceutical cancer therapy

Mr Nwokwu emphasised that the differences in treatment across the stages reinforced the importance of detecting cancer early, before it spreads beyond the organ where it originated.

He said early diagnosis allowed doctors to determine the stage of the disease and select the most appropriate combination of treatment modalities.

The coordinator also emphasised that cancer treatment should be individualised because cancers affecting the same organ could behave differently depending on their biological characteristics.

He urged Nigerians to seek medical attention promptly when they notice unusual symptoms and to follow appropriate screening and diagnostic recommendations to improve the chances of detecting cancer at an early stage.
(NAN)


Discover more from Premium Times Nigeria

Subscribe to get the latest posts sent to your email.

Continue Reading

Health

FG deploys task force to respond to diphtheria outbreaks in Kano, Katsina

info

Published

on

By

IMG 20240321 WA0010 e1711024943581.jpg

MTN ADVERT

The federal government has deployed an emergency multi-agency task force to strengthen surveillance, close immunisation gaps and expand access to treatment following diphtheria outbreaks in Kano and Katsina states.

Ado Bako, an Assistant Director in the Information and Public Relations Department of the Federal Ministry of Health and Social Welfare, disclosed this in a statement on Friday.

According to the statement, the Minister of Health and Social Welfare, Muhammad Pate, directed the establishment of the task force as part of efforts to protect children and strengthen Nigeria’s capacity to prevent and respond to disease outbreaks.

“The federal government reaffirms its resolve to protect Nigerian children from vaccine preventable diseases and remains committed to a swift, coordinated and evidence based response to bring the outbreak under control,” the statement said.

The development follows reports of deaths among children in Rano Local Government Area of Kano State.

PT WHATSAPP CHANNEL

On Wednesday, a lawmaker in the Kano State House of Assembly raised the alarm over a severe diphtheria outbreak in the area and called for urgent intervention.

Diphtheria

Diphtheria is a serious and highly contagious bacterial infection caused by Corynebacterium diphtheriae.

The infection spreads mainly through respiratory droplets when an infected person coughs or sneezes, as well as through close contact with an infected person.

Common symptoms include fever, sore throat and the development of a thick grey or white membrane in the throat, which can obstruct breathing. Severe cases can cause complications such as heart and nerve damage.

Vaccination with diphtheria toxoid containing vaccines, including the pentavalent vaccine routinely administered to infants, remains the most effective protection against the disease.

Nigeria has recorded more than 40,000 suspected diphtheria cases and over 1,000 deaths since the outbreak began in 2022.

Multi agency response

The newly established task force will coordinate the federal and state response and comprises the Federal Ministry of Health and Social Welfare, the Nigeria Centre for Disease Control and Prevention (NCDC), the National Primary Health Care Development Agency (NPHCDA), affected state governments and international health partners.

The committee will be jointly led by the Director General of the NCDC and the Director of Public Health, who will serve as co chairs.

Its members include representatives of the NPHCDA; health commissioners from Katsina, Kano, Zamfara and Sokoto states; the World Health Organisation (WHO); the United Nations Children’s Fund (UNICEF); and the National Tuberculosis and Leprosy Control Programme in Katsina.

The ministry’s chief epidemiologist will serve as secretary of the committee.

Vaccination and treatment

The task force will focus on containing the outbreak by investigating cases, strengthening disease surveillance and intensifying community sensitisation.

It will also work to identify and immunise children who have not received the required vaccines, particularly in communities where immunity gaps may be contributing to the spread of the disease.

As part of the immediate response, the NPHCDA has deployed 500,000 doses of vaccines to Kano and Katsina states.

READ ALSO: Kano community rejects bribe, reports drug trafficking network – Agency

Beyond vaccination, the task force is working with the Katsina State government to establish hospital treatment annexes across the Katsina, Daura and Funtua senatorial districts.

The annexes are expected to facilitate early treatment and bring care closer to affected communities.

Emergency support is also being mobilised for referral services at the Federal Teaching Hospital in Katsina, which serves as the primary treatment centre for the state and neighbouring areas.

The support includes supplies of diphtheria antitoxin (DAT), intravenous antibiotics, additional clinical personnel and personal protective equipment (PPE).

The task force will provide the minister with weekly updates on the response, including emerging challenges and additional requirements, to ensure that identified bottlenecks are promptly addressed.


Discover more from Premium Times Nigeria

Subscribe to get the latest posts sent to your email.

Continue Reading

Trending